These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 13124814)

  • 1. A heparin-retarded plasma clotting test.
    POLLER L
    Angiology; 1954 Feb; 5(1):21-6. PubMed ID: 13124814
    [No Abstract]   [Full Text] [Related]  

  • 2. An improved plasma recalcified clotting test and its modification as a simple rapid heparin retarded clotting test.
    EASTHAM RD
    J Clin Pathol; 1962 Jan; 15(1):86-7. PubMed ID: 13888970
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in blood coagulation following coronary thrombosis measured by the heparin retarded clotting test (Waugh and Ruddick test).
    OGURA JH; FETTER NR
    J Clin Invest; 1946 Jul; 25(4):586-96. PubMed ID: 21001633
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in blood coagulation following coronary thrombosis measured by the heparin retarded clotting test (Waugh and Ruddick test).
    OGURA JH; FETTER NR
    Proc Annu Meet Cent Soc Clin Res U S; 1945; 18():47. PubMed ID: 21021618
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the sensitivity of an in vitro high frequency ultrasound device to monitor the coagulation process: study of the effects of heparin treatment in a murine model.
    Callé R; Rochefort GY; Desbuards N; Plag C; Antier D; Ossant F
    Ultrasound Med Biol; 2010 Feb; 36(2):295-305. PubMed ID: 20045589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of heparin on three whole blood activated clotting tests and thrombin time.
    Uden DL; Seay RE; Kriesmer PJ; Cipolle RJ; Payne NR
    ASAIO Trans; 1991; 37(2):88-91. PubMed ID: 1854557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time measurement of free thrombin: evaluation of the usability of a new thrombin assay for coagulation monitoring during extracorporeal circulation.
    Krajewski S; Krauss S; Kurz J; Neumann B; Schlensak C; Wendel HP
    Thromb Res; 2014 Mar; 133(3):455-63. PubMed ID: 24359968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
    Zmuda K; Neofotistos D; Ts'ao CH
    Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similarity to Heparin of the Clotting Inhibitor in Acute Leucemia and the Significance of Hyperheparinemia in Estrapenic Cholinergic States.
    Barnard RD
    Science; 1948 May; 107(2787):571-2. PubMed ID: 17779205
    [No Abstract]   [Full Text] [Related]  

  • 12. Thrombin clotting time.
    Ignjatovic V
    Methods Mol Biol; 2013; 992():131-8. PubMed ID: 23546710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of intravascular clotting tendency by heparin tolerance principle; methods and clinical application.
    TUFT HS; ROSENFIELD RE
    Am J Clin Pathol; 1947 Nov; 17(11):862-5. PubMed ID: 20269992
    [No Abstract]   [Full Text] [Related]  

  • 14. Mitigation of coagulation by removing clotting factors part 2: heparin-free extracorporeal circulation in a porcine model.
    Sukavaneshvar S; Parker JT; Beutler DS; Burns G; Solen KA; Mohammad SF
    ASAIO J; 2007; 53(4):421-7. PubMed ID: 17667225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation protein function: the influence of acetaldehyde-modified heparin on thrombin activity.
    Brecher AS; Fu Q
    J Investig Med; 1999 Jan; 47(1):76-80. PubMed ID: 10071484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research review: use of activated clotting time to monitor heparin therapy in coronary patients.
    Noureddine SN
    Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
    Kurec AS; Morris MW; Davey FR
    Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of surface induced coagulation by preadsorption of albumin-heparin conjugates.
    Hennink WE; Kim SW; Feijen J
    J Biomed Mater Res; 1984 Oct; 18(8):911-26. PubMed ID: 6544786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
    Huyzen RJ; van Oeveren W; Wei F; Stellingwerf P; Boonstra PW; Gu YJ
    Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.